New pill aims to extend remission in rare blood cancer
NCT ID NCT07347288
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called SHR2554 as a maintenance therapy for people with peripheral T-cell lymphoma who have responded to initial treatment. The goal is to see if taking this pill can help keep the cancer from progressing for longer. About 30 adults who have achieved complete or partial remission after first-line therapy will take SHR2554 and be monitored for side effects and disease control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PTCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug spare healthy cells while killing lymphoma?
- Can a targeted pill boost Chemo's power against a rare blood cancer?
- New study aims to decode PTCL by genetic subtype
- New hope for tough lymphoma: TR115 faces off against standard care
- New CAR-T therapy targets tough T-Cell cancers in early trial
- New drug cocktail takes on hard-to-treat lymphomas